Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC102 + Temozolomide in Advanced Solid Tumors and Lymphomas
NCT01851369Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2013
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methoxyamine hydrochloride in solid tumor, lymphoma, colon carcinoma and 2 more, sponsored by National Cancer Institute. Primary endpoints: Response Rate of This Combination in Participants With Colon Cancer, Non-small Cell Lung Cancer (NSCLC), and Granulosa Cell Ovarian Cancer at 1 year, The Number of Dose Limiting Toxicities Observed in Participants Receiving Oral TRC102 in Combination With Oral TMZ at 28 days and 4 more. Started Jul 2013; status: completed.
02
Drugs
methoxyamine hydrochloride
03
Conditions
solid tumorlymphomacolon carcinomanon-small cell lung cancer (NSCLC)granulosa cell tumor of the ovary (GCT)
Beyond the preview
Go deeper on NCT01851369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01851369.